Expanding Into Southeast Asia: Which Market Should You Enter First?

The standard advice is "start with Singapore." The reasoning is usually: English-language, highly organized regulatory system, FDA and CE recognition pathways, serves as a regional hub, and you can use the Singapore registration to support other ASEAN markets later. This advice is not wrong. But it's also not universally right, and following it mechanically without considering your specific situation can lead to suboptimal sequencing.

Here's a framework for thinking through the market entry sequence question with the variables that actually matter.

The Singapore-first case: when it makes sense

Singapore-first makes the most sense when:

Your device is high-risk (Class C/D equivalent). High-risk devices require the most rigorous regulatory review everywhere. Singapore's HSA, while rigorous, is faster and more predictable than BPOM, MDA, or FDA-TH for Class C/D-equivalent devices. Getting through Singapore establishes a regional track record and sometimes supports other market applications. If you're going to have a 12-month review somewhere anyway, Singapore is the one with the most reliable timeline and the most legible process.

You need regional clinical evidence. Singapore's hospitals are sophisticated and produce publication-quality clinical data. A clinical study conducted in Singapore — at National University Hospital, Singapore General Hospital, or one of the major private hospital groups — carries weight when submitting to other Asian regulators. If your market entry strategy involves building a regional clinical evidence base, Singapore is the place to start generating it.

Your team has limited Asia experience. Singapore's regulatory environment is the most similar to Western regulatory environments (organized, English, rule-based, transparent). For companies building their Asia regulatory muscle for the first time, Singapore is a reasonable place to learn the system before handling more complex markets.

You're building a regional hub strategy. If your commercial model involves Singapore as a regional headquarters with distribution managed from there, it's logical to establish regulatory presence there first.

The case against Singapore-first

Singapore has 5.9 million people. It's a wealthy country with sophisticated healthcare — but it's not where the volume is. For most medical device categories, Singapore will not be a major revenue market in absolute terms. The revenue potential in Indonesia (280 million people), Vietnam (100 million people), and Thailand (70 million people) dwarfs Singapore.

A Singapore registration does not transfer to Indonesia or Malaysia. Each market requires its own independent registration. The regulatory systems are distinct enough that Singapore registration provides background context but not a shortcut in other markets. A company that spends 12 months getting Singapore right and then needs another 12–18 months for Indonesia has spent 2–3 years before accessing the largest market in the region.

For companies with resource constraints — which includes most companies that aren't already large multinationals — Singapore-first can delay meaningful revenue access.

The Indonesia-first case: when it makes sense

Indonesia is the largest market in Southeast Asia by population and arguably by long-term medical device opportunity. The BPOM registration process is more complex and slower than Singapore's, but it's navigable with the right local consultant and a well-prepared dossier.

Indonesia-first makes sense when:

Your device is Class A or B. Lower-risk devices have shorter BPOM review timelines and less demanding technical documentation requirements. The complexity gap between Indonesia and Singapore is smaller for Class B than for Class C/D. If you can get a Class B device registered in Indonesia in 6–9 months, the calculus changes relative to the Singapore-first model.

Your device addresses a high-volume need. Wound care, disposable consumables, basic diagnostics — categories where Indonesia's volume justifies the regulatory investment even if the per-unit margin is lower than high-risk devices.

Your distributor network is Indonesia-centric. If you've already identified a strong Indonesian distributor with good BPOM relationships and a track record of efficient registration management, the practical barriers to Indonesia-first are lower than the theoretical framework suggests.

The Japan question

Japan sits outside the Southeast Asia sequencing question but belongs in any serious discussion of Asian market entry. Japan is the third-largest medical device market globally, with revenue potential that dwarfs the entire ASEAN region combined for many device categories.

Japan should be in your planning horizon even if it's not your first entry market. The reason: Japan's entry process (PMDA shonin or ninsho, Marketing Authorization Holder establishment) takes the longest of any market covered here. Starting the Japan planning process — or initiating preliminary conversations with potential MAH partners — several years before you expect to sell in Japan is appropriate for high-risk devices.

If Japan is eventually important to your strategy, the sequencing question isn't just about Southeast Asia; it's about resource allocation between the relatively accessible Southeast Asian markets and the high-investment Japan market. Companies that try to do Japan and multiple Southeast Asian markets simultaneously often underresource all of them.

Korea and Vietnam as strategic additions

South Korea, with its FDA/CE recognition pathway, often fits naturally into the sequence after Singapore or as part of a parallel track. If you have US FDA 510(k) clearance and a Singapore HSA registration, Korea can follow relatively quickly — the documentation overlap is meaningful and the timeline advantages of the recognition pathway are real.

Vietnam deserves more attention than it typically gets in market entry conversations. The reference country fast-track pathway — applicable to devices already cleared by FDA, CE, TGA, Health Canada, or PMDA — makes Vietnam accessible for companies with established regulatory credentials. Vietnam's healthcare market is growing quickly and is currently underpenetrated for many device categories. For companies that can leverage the reference pathway, Vietnam can be entered with relatively modest incremental investment.

The research-first framework

Rather than following a standard sequencing heuristic, the better approach is to research what's actually happening in each target market before deciding where to go first:

1. Check where your direct competitors are registered. If your three main competitors are all in Indonesia but none are in Vietnam, that tells you something about where the commercial opportunity is concentrated. If a competitor just started registering in a market they weren't in before, they've done the analysis — you can benefit from reading their strategic signal.
2. Look at device category density. How many active registrations exist in your device category in each market? High density means established competitive market. Low density might mean opportunity — or it might mean the market economics don't support the device category.
3. Assess your device class in each target market. The same device may be classified differently in different markets. Your Class B Indonesia filing might be Class C in Thailand. This classification difference affects the review timeline, the documentation burden, and the overall cost of market entry in each market.
4. Evaluate your distributor network. Where do you have strong potential distributor relationships? An excellent distributor in Malaysia with good MDA relationships is worth considering even if Malaysia isn't the largest market, because the execution risk is lower.

The recommendation

There is no universally correct answer. The right first market depends on your device class, your distributor relationships, your resource constraints, and the competitive landscape in your specific device category. What the "Singapore first" heuristic gets right is risk management — Singapore is the most legible first step. What it misses is the revenue dimension — Singapore isn't where the volume is, and delaying access to larger markets has real costs.

The companies that execute Asian expansion best are the ones who research the specific market conditions for their specific device — including registration landscape, competitor presence, and commercial infrastructure — before committing to a sequence. Registration data is the fastest way to get that market-specific picture.